Spyre CEO Sells $740K in Stock After 300% Surge as Key Q3 Data Nears [Yahoo! Finance]
Spyre Therapeutics, Inc. (SYRE)
Company Research
Source: Yahoo! Finance
Transaction summary Metric Value Shares sold (direct) Transaction value ~$740K Post-transaction shares (direct) Post-transaction value (direct ownership) ~$30.69 million Transaction value based on SEC Form 4 weighted average purchase price ($49.33); post-transaction value based on April 1, 2026 market close. Key questions How does this sale fit within Cameron Turtle's historical trading activity? Since May of last year, Turtle has made six batches of sell transactions, with this 15,000-share disposal matching the most frequent recent trade size and consistent with the four sales executed since January 2026. What proportion of direct holdings did this sale represent? This transaction accounted for 2.33% of Turtle's direct common shareholdings at the time, a figure in line with the per-sale percentages seen in the recent period as holdings have gradually declined. Were any options, indirect entities, or share classes involved? All shares sold were direct
Show less
Read more
Impact Snapshot
Event Time:
SYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRE alerts
High impacting Spyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SYRE
News
- Spyre Therapeutics Announces Grants of Inducement AwardsGlobeNewswire
- Spyre Therapeutics (SYRE) had its "buy" rating reaffirmed by BTIG Research. They now have a $70.00 price target on the stock.MarketBeat
- Assessing Spyre Therapeutics (SYRE) Valuation After Strong One Year Return And Premium Price To Book Ratio [Yahoo! Finance]Yahoo! Finance
- Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics (SYRE) had its price target raised by Stifel Nicolaus from $70.00 to $92.00. They now have a "buy" rating on the stock.MarketBeat
SYRE
Earnings
- 11/4/25 - Beat
SYRE
Sec Filings
- 4/3/26 - Form 4
- 4/3/26 - Form 4
- 4/3/26 - Form 4
- SYRE's page on the SEC website